Insmed Incorporated · INSM · FY2026 Q3 · Calendar Q4 2026
Insmed raises revenue outlook as BRINSUPRI passes $1 billion
The quarter supports the view that strong launch execution and resilient demand can underpin continued growth: BRINSUPRI reached blockbuster scale in its first year, guidance increased, and management cited a broad respiratory pipeline. The thesis remains dependent on persistence, regulatory progress, commercialization of new indications and a path to cash-flow positivity.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about INSM FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, BRINSUPRI advanced from a strong launch to more than $1 billion in first-year sales, full-year revenue guidance increased, and ARIKAYCE received FDA priority review. Management also highlighted new AI diagnostic work and a wider development slate, while maintaining its 2027 cash-flow-positive objective.
Guidance delta
Management raised full-year revenue guidance to $1.35-$1.40 billion from the prior $1.25-$1.40 billion range.
Key takeaways
- BRINSUPRI generated $400.1 million in the quarter and exceeded $1 billion in its first four quarters, according to management
- ARIKAYCE received FDA priority review for its supplemental NDA, with a PDUFA target of January 28, 2027
- Management continues to target cash-flow positivity in 2027 while investing in respiratory pipeline programs
Management priorities
- Expand BRINSUPRI through broader diagnosis, physician education and its first branded television campaign
- Advance TPIP, INS1033, INS1148 and gene-therapy programs
- Pursue ARIKAYCE label expansion and continue real-world evidence and AI diagnostic initiatives
Follow INSM with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationInsmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| WST West Pharmaceutical Services, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +7.7% | West Pharmaceutical raises 2026 guidance as HVP demand drives Q3 growth |
| TAK Takeda Pharmaceutical Company Limited | FY2026 Q2 · Calendar Q4 2026 | — | -1.0% | Takeda maintains FY2026 guidance as launches and savings advance |
| ALGN Align Technology, Inc. | FY2026 Q3 · Calendar Q4 2026 | +1.1% | +1.1% | Align lowers 2026 guidance as consumer demand softens |
| GKOS Glaukos Corporation | FY2026 Q3 · Calendar Q4 2026 | +587.8% | +0.1% | Glaukos raises 2026 guidance after strong Epioxa and iDose growth |
| GEHC GE HealthCare Technologies Inc. | FY2026 Q3 · Calendar Q4 2026 | +11.7% | +6.6% | GE HealthCare raises 2026 outlook as margins expand |
| LH Labcorp Holdings Inc. | FY2026 Q3 · Calendar Q4 2026 | +3.0% | +8.8% | Labcorp raises 2026 outlook as specialty testing drives Q3 growth |
Latest beats and misses
Who reports nextBeat on EPS
- KGCFY2026 Q3 · October 28, 2026+8.7% EPS-6.1% move
- GENFY2027 Q2 · October 28, 2026+2.9% EPS+11.2% move
- KLACFY2027 Q1 · October 28, 2026+2.5% EPS+7.3% move
- SANFY2026 Q3 · October 28, 20260.0% EPS-6.3% move
- FFY2026 Q3 · October 28, 2026+19.5% EPS+1.4% move
- EQIXFY2026 Q3 · October 28, 2026+20.0% EPS+5.4% move
Missed on EPS
- AWKFY2026 Q3 · October 28, 2026-2.0% EPS+1.1% move
- CPFY2026 Q3 · October 28, 2026-3.2% EPS-1.9% move
- LIIFY2026 Q3 · October 28, 2026-7.1% EPS-10.6% move
- EXRFY2026 Q3 · October 27, 2026-1.7% EPS+0.1% move
- NOWFY2026 Q3 · October 28, 2026-2.0% EPS-3.0% move
- CMGFY2026 Q3 · October 28, 2026-7.1% EPS+2.7% move
Get the INSM recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-29T17:09:47.981412+00:00
- FN2 earnings calendar · 2026-10-29T01:23:20.584741+00:00
- Polygon adjusted daily market bars · 2026-10-29T17:20:44.188797+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-29T17:20:44.186189+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-29. For educational purposes only; not investment advice.